HRAS and breast carcinoma: RAS p21 in the context of breast cancer was first described in 1984, with Hand et al. demonstrating that 90% of invasive ductal carcinomas show positive staining for RAS p21 [27], followed by reports on the expression in primary and metastatic breast cancer [28, 29].